Humanized monoclonal antibody directed against complement component C5; designed to prevent activation of complement-mediated inflammation and tissue injury. Prepn: M. J. Evans et al., WO 9529697; eidem, US 6355245 (1995, 2002 both to Alexion); and complement inhibition study: T. C. Thomas et al., Mol. Immunol. 33, 1389 (1996). Overview of development and therapeutic potential: M. Kaplan, Curr. Opin. Investig. Drugs 3, 1017-1023 (2002). Clinical trial in paroxysmal nocturnal hemoglobinuria: P. Hillmen et al., N. Engl. J. Med. 355, 1233 (2006).
Anti-inflammatory.
Anti-inflammatory (Biological Response Modifier)